ViroGates: A suPARhighway to health (Västra Hamnen)
Västra Hamnen Corporate Finance initiates research coverage on the Danish medical technology company ViroGates A/S. The initial valuation range is set at DKK 68.00 - 100.50 per share given the present level of risk.
- A simple blood test to immensely improve clinical decision making
- Global market opportunities and virtually no competition
- We see a fair value of DKK 68.00 – 100.50 per share in Acute Care alone
ViroGates has developed a prognostic biomarker, suPARnostic®, that can assist physicians in deciding which patients need immediate attention and which patients can safely be discharged from hospital. This is achieved by measuring the level of suPAR from a quick blood sample. Further out, suPARnostic® could become an important aid in motivating and reinforcing lifestyle changes in currently healthy individuals, hindering the development of lifestyle-related diseases years later.
A huge body of research supports the efficacy of the method. The solution contributes to significant efficiency gains in the healthcare system, which
are acutely needed as several societal megatrends are putting increasing strain on the health sector. The company is also well protected from competition by a combination of technical leadership and patents.
Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model. We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.
The full report is available here.
The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.
This is a press release from Västra Hamnen Corporate Finance AB.
Web: vhcorp.se
Twitter: @vhcorp_se